FDA allows marketing of test to aid in the detection of certain leukemias and lymphomas
The U.S. Food and Drug Administration today allowed marketing of ClearLLab Reagents (T1, T2, B1, B2, M), the first agency authorized test for use with flow cytometry to aid in the detection of several leukemias and lymphomas, including chronic leukemia, acute leukemia, non-Hodgkin lymphoma, myeloma, myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPN).
Acta Haematol 2017;138:198-200
This is an exciting time for leukemia research, with the latest research using bispecifics revealing positive outcomes for patients. Here, Prof. John DiPersio, MD, PhD of Washington University School ... Author: VJHemOnc Added: 11/23/2017
It is crucial that drug toxicity is kept as low as possible to improve the quality of life of patients. Speaking from the International Conference on Acute Myeloid Leukaemia 2017, Estoril, Portugal by... Author: VJHemOnc Added: 11/23/2017
This is an exciting time for acute myeloid leukemia (AML) treatment, with multiple new therapies being investigated currently. In this interview, Francesco Lo-Coco, MD, from the University Tor Vergata... Author: VJHemOnc Added: 11/23/2017
ConclusionAmong the comorbidities that compose the HCT‐CI, diabetes and cardiovascular comorbidity independently predict NRM in patients undergoing allogeneic HCT for AML. This information should be taken into consideration regarding post‐transplant monitoring and care.This article is protected by copyright. All rights reserved.
Authors: Tadmor T, Welslau M, Hus I Abstract INTRODUCTION: The majority of patients with chronic lymphocytic leukemia (CLL) will obtain an infectious complication at some point during their disease, accounting for up to an estimated 60% of deaths in CLL. Patients are predisposed to infection due to inherent immune defects related to the primary disease, and as a result of therapy. The range of infectious complications has evolved alongside therapeutic advances in the treatment of CLL. More recently several novel targeted therapeutic compounds have been introduced in CLL, whose unique safety profiles will probably h...
In this study, we collected 8 cases of primary cutaneous small cell variant of ALCL and examined their clinical, histologic, and phenotypic features. All patients were middle aged to older adult men; the youngest patient was a 46-year-old man with underlying hepatitis C. In one case, there was a history of lymphomatoid papulosis. In all patients, the disease was in the context of a local regional presentation. Patients were treated with complete excision and/or radiation except in one in whom chemotherapy was administered. In all but one patient, the cutaneous presentation was a regionally confined process; however, in 2 c...
We report the case of a 35-year-old man who underwent allogenic stem cell transplantation for a therapy-associated acute myeloid leukemia and developed an acute GvHD with involvement of skin and gastrointestinal tract. He subsequently presented with chronic sclerodermatous cutaneous GvHD, followed by the appearance of indurated erythematous papules and plaques located on his back, resembling the nodular/keloidal form of cutaneous scleroderma on both clinical and histopathological grounds. This peculiar clinicopathologic presentation of chronic cutaneous GvHD was never described previously.
We report a case of a 36-year-old man who presented with erythematous, studded papules and plaques on the left upper extremity and right anterior thigh diagnosed as mycosis fungoides (MF) Stage 1A on initial superficial shave biopsy. Lesions recurred after initial improvement with narrow-band ultraviolet light therapy demonstrating a concentration of abnormal lymphocytes around eccrine sweat glands on repeat biopsy consistent with STMF. Although the deeper, periadnexal infiltrate found in both STMF and FMF confers increased resistance to skin-directed therapies effective in classic MF, these entities diverge with respect t...